Equities analysts predict that Allscripts (NASDAQ:MDRX) will report sales of $533.09 million for the current fiscal quarter, according to Zacks Investment Research. Ten analysts have made estimates for Allscripts’ earnings, with the lowest sales estimate coming in at $505.70 million and the highest estimate coming in at $552.10 million. Allscripts reported sales of $415.10 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 28.4%. The firm is expected to announce its next quarterly earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that Allscripts will report full year sales of $533.09 million for the current fiscal year, with estimates ranging from $2.16 billion to $2.22 billion. For the next financial year, analysts anticipate that the firm will report sales of $2.29 billion per share, with estimates ranging from $2.22 billion to $2.34 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow Allscripts.
Allscripts (NASDAQ:MDRX) last issued its quarterly earnings results on Thursday, February 15th. The software maker reported $0.18 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.18. Allscripts had a negative net margin of 10.88% and a positive return on equity of 7.36%. The company had revenue of $547.00 million during the quarter, compared to the consensus estimate of $524.05 million. During the same quarter in the prior year, the firm posted $0.14 EPS. The firm’s quarterly revenue was up 27.5% on a year-over-year basis.
MDRX has been the subject of a number of research analyst reports. Citigroup initiated coverage on shares of Allscripts in a research report on Thursday, January 4th. They set a “buy” rating for the company. Royal Bank of Canada set a $19.00 price objective on shares of Allscripts and gave the stock a “buy” rating in a research report on Thursday, January 11th. Zacks Investment Research upgraded shares of Allscripts from a “sell” rating to a “hold” rating in a research report on Thursday, January 25th. BidaskClub cut shares of Allscripts from a “buy” rating to a “hold” rating in a research report on Wednesday, March 14th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $17.00 price objective on shares of Allscripts in a research report on Monday, January 8th. Three analysts have rated the stock with a sell rating, five have given a hold rating and eleven have assigned a buy rating to the company’s stock. Allscripts has an average rating of “Hold” and an average price target of $16.22.
In other Allscripts news, President Richard J. Poulton sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $13.53, for a total value of $202,950.00. Following the completion of the transaction, the president now directly owns 505,920 shares in the company, valued at approximately $6,845,097.60. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Brian Farley sold 5,000 shares of the stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $13.73, for a total transaction of $68,650.00. Following the sale, the executive vice president now owns 240,672 shares of the company’s stock, valued at $3,304,426.56. The disclosure for this sale can be found here. Corporate insiders own 0.91% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Zeke Capital Advisors LLC acquired a new stake in shares of Allscripts during the fourth quarter worth $165,000. Sheaff Brock Investment Advisors LLC acquired a new stake in shares of Allscripts during the third quarter worth $174,000. Quantitative Systematic Strategies LLC acquired a new stake in shares of Allscripts during the fourth quarter worth $182,000. Avestar Capital LLC acquired a new stake in shares of Allscripts during the fourth quarter worth $173,000. Finally, Crossmark Global Holdings Inc. acquired a new stake in shares of Allscripts during the third quarter worth $187,000.
MDRX stock traded up $0.02 during trading on Monday, reaching $12.15. 2,033,548 shares of the company were exchanged, compared to its average volume of 2,057,263. The stock has a market cap of $2,193.72, a price-to-earnings ratio of 25.85, a P/E/G ratio of 1.56 and a beta of 1.23. Allscripts has a twelve month low of $10.78 and a twelve month high of $16.13. The company has a debt-to-equity ratio of 1.33, a current ratio of 0.97 and a quick ratio of 0.97.
ILLEGAL ACTIVITY NOTICE: “Allscripts (MDRX) Expected to Post Quarterly Sales of $533.09 Million” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/04/09/allscripts-mdrx-expected-to-post-quarterly-sales-of-533-09-million.html.
Allscripts Company Profile
Allscripts Healthcare Solutions, Inc provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions.
Get a free copy of the Zacks research report on Allscripts (MDRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allscripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts and related companies with MarketBeat.com's FREE daily email newsletter.